Intellia (NTLA) Will Report Q1 Earnings: What's Next? – April 25, 2024

We expect investors to focus on Intellia Therapeuticsof(north Free Report) is making progress in the development of its portfolio of CRISPR-based gene editing therapies as it reports first-quarter 2024 earnings.

Factors to note

Intellia's revenue currently includes collaboration revenue only.Last quarter's revenue was impacted by a $10.3 million recognition adjustment due to Regeneron Pharmaceuticals (rain Free report) extends technical cooperation until April 2026.

However, NTLA is eligible for a $30 million payment as part of the REGN extension.

Intellia is collaborating with Regeneron to develop its investigational in vivo genome editing drug candidate NTLA-2001.

In March 2024, the company dosed the first patient in the Phase III MAGNITUDE study evaluating NTLA-2001 for the treatment of transporting transthyretin (ATTR) amyloidosis.

The placebo-controlled MAGNITUDE study will evaluate the safety and efficacy of NTLA-2001 in patients with ATTR amyloid cardiomyopathy.

If data from the MAGNITUDE study are positive, it would enable the drug to undergo regulatory filings around the world.

Investors will be eager to get more updates on NTLA-2001's future path during its upcoming earnings call.

Year to date, NTLA shares have fallen 30.6%, compared with the industry's decline of 9.4%.

NTLA-2001 is also being developed for the treatment of hereditary ATTR amyloidosis with polyneuropathy. An update on this additional metric from the NTLA-2001 pivotal Phase III study is expected to be released on the upcoming earnings call.

Updates on Intellia's other genome-editing therapy, NTLA-2002, which is being evaluated in a Phase I/II study to treat hereditary angioedema, are also expected to be released on the upcoming earnings call.

Activities related to product candidate development are likely to result in increased operating expenses for Intellia in the to-be-reported quarter.

Profit Surprise History

Intellia's history of earnings surprises so far has been mixed. The company's earnings have topped estimates in three of the last four quarters, while falling short in the remaining quarters. NTLA's average gain was 5.21%. In its last reported quarter, Intellia's profit beat estimates by 0.68%.

earnings whisper

Our proven model doesn't conclusively predict that Intellia will beat earnings estimates this time around. A positive Earnings ESP combined with a Zacks Rank #1 (Strong Buy), #2 (Buy), or #3 (Hold) increases the odds of earnings beating estimates. That's not the case here, as you'll see below. You can discover the best stocks to buy or sell before they report with our Earnings ESP filter.

Yield ESP: Intellia's Earnings ESP is -3.73%, as the most accurate estimate currently calls for a loss of $1.39 per share, while the Zacks Consensus Estimate is for a loss of $1.34 per share.

Zack's ranking: Intellia currently carries a Zacks Rank can see The complete list of today’s Zacks #1 Rank stocks is here.

Stocks worth considering

Here are some stocks in the healthcare space worth considering, as our model suggests they have the right combination of elements to beat on earnings this reporting cycle.

Sarepta Therapeutics, Inc. (SRPT Free Report) has an Earnings ESP of +108.99% and a Zacks Rank #2.

Year-to-date, Sarepta's shares are up 28.9%. Sarepta's profits have exceeded expectations in each of the past four quarters, with the average profit exceeding expectations by 464.56%. SRPT will announce first-quarter earnings results on May 1.

Algenx SE (arks Free Report) has an Earnings ESP of +15.09% and a Zacks Rank #3.

Argenx shares have fallen 1.4% so far this year. argenx has topped profit estimates in two of the last four quarters, hitting the same estimate once and missing expectations the other time. On average, ARGX's earnings surprise over the trailing four quarters was 14.18%.

Stay up to date with upcoming earnings announcements with the Zacks Earnings Calendar.

FREE – 5 Dividend Stocks to Fund Your Retirement

Zacks Investment Research has released a special report to help you prepare for retirement with 5 diversified stocks that pay huge dividends. They involve property management, high-end stores, financial institutions and some powerful energy producers.

5 Dividend Stocks to Include in Your Retirement Strategy Full of unconventional wisdom and insights you won't get from your neighborhood financial planner.

Download Now – It’s Free Today >>

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *